Early IP Strategy for Life Sciences Start-Ups Pays off

We explain the 5 biggest pitfalls

par Dr. Anja Lunze, LL.M. et Tobias Baus, LL.M., Dipl.-Ing.

Advising on Mission Zero Technologies on its £21.8 million Series A funding

par Ross McNaughton et Oli Denne

SPC waivers explained by the District Court of The Hague

par Iris van der Heijdt

Advising Bridgepoint on its investment in Identicare

par Emma Danks et Jonny Bethell

The UPC Appeal Court overturns the 10x Genomics PI, but focuses on validity

par plusieurs auteurs

Three novelties in the Belgian reference reimbursement system relevant for patent litigation

par Séverine Bouvy

Forum Shopping at the UPC

Different routes for infringement and revocation proceedings?

par plusieurs auteurs

Trade Mark Opposition proceedings in the Benelux – new guidelines

par Saskia van der Meijden-Bullens

Claim construction in the UPC: The case SES-Imagotag v Hanshow.

par plusieurs auteurs

Early IP Strategy for Life Sciences Start-Ups Pays off

We explain the 5 biggest pitfalls

par Dr. Anja Lunze, LL.M. et Tobias Baus, LL.M., Dipl.-Ing.

Advising on Mission Zero Technologies on its £21.8 million Series A funding

par Ross McNaughton et Oli Denne

SPC waivers explained by the District Court of The Hague

par Iris van der Heijdt

Advising Bridgepoint on its investment in Identicare

par Emma Danks et Jonny Bethell

The UPC Appeal Court overturns the 10x Genomics PI, but focuses on validity

par plusieurs auteurs

Three novelties in the Belgian reference reimbursement system relevant for patent litigation

par Séverine Bouvy

Forum Shopping at the UPC

Different routes for infringement and revocation proceedings?

par plusieurs auteurs

Trade Mark Opposition proceedings in the Benelux – new guidelines

par Saskia van der Meijden-Bullens

Claim construction in the UPC: The case SES-Imagotag v Hanshow.

par plusieurs auteurs